OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Optimising anal cancer screening through risk stratification	432
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	163
How do we prevent anal cancer in people living with HIV?	136
The Australian AIDS crisis through the eyes of volunteers	133
HIV and COVID-19: juxtaposition of two pandemics	126
Evidence supports use of on-demand PrEP for HIV prevention	120
Lung cancer in people living with HIV	118
Argentina updates HIV laws	116
Transplant donation without discrimination	116
How much could long-acting PrEP cost in South Africa?	107
Steps toward quick and equitable roll-out of lenacapavir	105
Controversial chronicler of LGBTQ rights	98
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV	98
Correction to Lancet HIV 2022; 9: e791–800	81
A moment of reckoning	76
Are we ready for long-acting HIV treatment for adolescents?	69
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	68
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	67
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	64
Lenacapavir: an attractive option, but proceed with caution	62
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	62
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	60
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	60
Risk estimation in HIV reveals our usual blind spots	59
All roads lead to Westminster: the infected blood scandal	57

Redefining care: injectable HIV treatment for adolescents	55
Making America unhealthy again	55
Equitable access to long-acting PrEP on the way?	54
Recent gay Black history in the UK	53
Reducing HIV transmission in British Columbia, Canada	51
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	49
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys	48
Suicide prevention research is crucial to achieving health equity for people with HIV	47
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:	47
Game-changing study of second-line HIV treatment	46
Unheard testimony	46
Gains and gaps: addressing HIV in diverse sex worker groups	46
Dolutegravir in neonates: finally we are getting there!	45
Integration of sexual health and HIV services	45
Sex as a biological variable in HIV-1 and schistosome co-infection	44
WHO recommends lenacapavir for HIV prevention	43
Preventing tuberculosis in advanced HIV disease	43
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	42